Richard Fisher

8.9k total citations · 4 hit papers
112 papers, 6.2k citations indexed

About

Richard Fisher is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Richard Fisher has authored 112 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 41 papers in Surgery and 37 papers in Oncology. Recurrent topics in Richard Fisher's work include Head and Neck Cancer Studies (23 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Richard Fisher is often cited by papers focused on Head and Neck Cancer Studies (23 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Richard Fisher collaborates with scholars based in Australia, United States and New Zealand. Richard Fisher's co-authors include Danny Rischin, Lester J. Peters, Rodney J. Hicks, Brian O’Sullivan, June Corry, Liz Kenny, Bev McClure, Bryan Burmeister, David Binns and J. Giralt and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Surgery.

In The Last Decade

Richard Fisher

109 papers receiving 6.1k citations

Hit Papers

Randomized Trial of Short-Co... 1985 2026 1998 2012 2012 2010 2010 1985 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04
    2012 585 citations Samuel Y. Ngan, Bryan Burmeister et al. Journal of Clinical Oncology profile →
  2. Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
    2010 571 citations Danny Rischin, Richard J. Young et al. Journal of Clinical Oncology profile →
  3. Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
    2010 548 citations Lester J. Peters, Brian O’Sullivan et al. Journal of Clinical Oncology profile →
  4. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer
    1985 387 citations Richard Fisher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Fisher Australia 37 2.5k 2.0k 1.8k 1.4k 1.3k 112 6.2k
Bhadrasain Vikram United States 40 2.2k 0.9× 2.3k 1.1× 1.6k 0.9× 1.2k 0.9× 2.0k 1.5× 148 5.9k
Eric J. Sherman United States 47 3.3k 1.3× 2.7k 1.3× 2.4k 1.3× 1.3k 0.9× 2.9k 2.2× 269 8.6k
Joseph K. Salama United States 45 2.8k 1.1× 2.5k 1.2× 3.7k 2.1× 1.1k 0.8× 1.4k 1.1× 217 7.2k
Volker Rudat Germany 33 1.3k 0.5× 2.4k 1.2× 1.8k 1.0× 1.3k 1.0× 1.3k 1.0× 128 5.4k
Roy H. Decker United States 39 2.0k 0.8× 878 0.4× 2.6k 1.4× 915 0.7× 740 0.6× 175 4.9k
Ranjan Sur Canada 18 3.0k 1.2× 2.2k 1.1× 3.0k 1.6× 661 0.5× 2.6k 2.0× 68 6.4k
Jiade J. Lu China 39 1.5k 0.6× 1.6k 0.8× 2.0k 1.1× 750 0.5× 1.6k 1.2× 186 4.5k
Jennifer Moughan United States 34 1.5k 0.6× 2.2k 1.1× 2.1k 1.2× 585 0.4× 1.1k 0.8× 123 4.9k
Ling‐Long Tang China 42 2.7k 1.1× 2.2k 1.1× 1.8k 1.0× 1.3k 0.9× 3.6k 2.7× 181 6.5k
Jean-Claude Horiot France 38 2.2k 0.9× 2.6k 1.3× 2.0k 1.1× 1.4k 1.0× 2.0k 1.5× 108 7.1k

Countries citing papers authored by Richard Fisher

Since Specialization
Citations

This map shows the geographic impact of Richard Fisher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Fisher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Fisher more than expected).

Fields of papers citing papers by Richard Fisher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Fisher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Fisher. The network helps show where Richard Fisher may publish in the future.

Co-authorship network of co-authors of Richard Fisher

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Fisher. A scholar is included among the top collaborators of Richard Fisher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Fisher. Richard Fisher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
MacManus, Michael, Richard Fisher, Daniel Roos, et al.. (2018). Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. Journal of Clinical Oncology. 36(29). 2918–2925. 66 indexed citations
2.
Phillips, Kelly‐Anne, Ian Collins, Roger L. Milne, et al.. (2016). Anti-Müllerian Hormone Serum Concentrations of Women With Germline BRCA1 or BRCA2 Mutations. Obstetrical & Gynecological Survey. 71(8). 474–475. 8 indexed citations
3.
4.
Trinkaus, Mateya, Rodney J. Hicks, Richard J. Young, et al.. (2014). Correlation of p16 status, hypoxic imaging using [18F]‐misonidazole positron emission tomography and outcome in patients with loco‐regionally advanced head and neck cancer. Journal of Medical Imaging and Radiation Oncology. 58(1). 89–97. 28 indexed citations
5.
Pearse, Maria, Carol Fraser‐Browne, Ian D. Davis, et al.. (2014). A P hase III trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage ( RAVES ) trial. British Journal of Urology. 113(S2). 7–12. 80 indexed citations
6.
7.
Le, Quynh‐Thu, Richard Fisher, Kelly S. Oliner, et al.. (2012). Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research. 18(6). 1798–1807. 41 indexed citations
8.
Burmeister, Bryan, Michael A. Henderson, Jill Ainslie, et al.. (2012). Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. The Lancet Oncology. 13(6). 589–597. 181 indexed citations
9.
Young, Richard J., Danny Rischin, Richard Fisher, et al.. (2011). Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 20(6). 1230–1237. 70 indexed citations
10.
Peters, Lester J., Brian O’Sullivan, J. Giralt, et al.. (2010). Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. Journal of Clinical Oncology. 28(18). 2996–3001. 548 indexed citations breakdown →
11.
Rischin, Danny, Richard J. Young, Richard Fisher, et al.. (2010). Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. Journal of Clinical Oncology. 28(27). 4142–4148. 571 indexed citations breakdown →
12.
Rischin, Danny, Richard J. Young, Richard Fisher, et al.. (2009). Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. Journal of Clinical Oncology. 27(15_suppl). 6004–6004. 30 indexed citations
13.
14.
Ow, Kim, Warick Delprado, Richard Fisher, et al.. (2000). Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. The Journal of Pathology. 191(1). 39–47. 29 indexed citations
15.
Berney, Christophe R., Richard Fisher, Jialin Yang, Pamela J. Russell, & Philip Crowe. (1999). Protein Markers in Colorectal Cancer. Annals of Surgery. 230(2). 179–179. 39 indexed citations
16.
Berney, Cédric, et al.. (1998). Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression.. PubMed. 10(1). 47–54. 13 indexed citations
17.
Bartoň, Michael, et al.. (1995). Breast cancer following treatment for Hodgkin's disease: The need for screening in a young population. Australasian Radiology. 39(3). 271–276. 16 indexed citations
18.
Mameghan, Hedy, et al.. (1993). Local failure in childhood rhabdomyosarcoma and undifferentiated sarcoma: Prognostic factors and implications for curative therapy. Medical and Pediatric Oncology. 21(2). 88–95. 8 indexed citations
19.
Mameghan, Hedy & Richard Fisher. (1989). Invasive Bladder Cancer. Prognostic Factors and Results of Radiotherapy with and without Cystectomy. British Journal of Urology. 63(3). 251–258. 27 indexed citations
20.
Freeman, Anthony P., R. Giles, Warren Walsh, et al.. (1985). Regional left ventricular wall motion assessment: Comparison of two-dimensional echocardiography and radionuclide angiography with contrast angiography in healed myocardial infarction. The American Journal of Cardiology. 56(1). 8–12. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bhadrasain Vikram Breakdown of academic impact, for papers by Eric J. Sherman Breakdown of academic impact, for papers by Joseph K. Salama Breakdown of academic impact, for papers by Volker Rudat Breakdown of academic impact, for papers by Roy H. Decker Breakdown of academic impact, for papers by Ranjan Sur Breakdown of academic impact, for papers by Jiade J. Lu Breakdown of academic impact, for papers by Jennifer Moughan Breakdown of academic impact, for papers by Ling‐Long Tang Breakdown of academic impact, for papers by Jean-Claude Horiot
Rankless by CCL
2026